Clinical trials: Recurrent or Metastatic Nasopharyngeal Carcinoma
Recurrent or Metastatic Nasopharyngeal Carcinom
Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11
NPC is a highly chemo-sensitive cancer. Platinum-containing doublet chemotherapy is regarded as the standard treatment for patients with recurrent or metastatic NPC, even though it has never been directly compared with supportive…
- Trial name
- HN17-11 (NCT06440187)
- Testing
- Gemcitabine+ nivolumab
- Where
- South Korea
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital